<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Mol Cancer</journal-id><journal-title>Molecular Cancer</journal-title><issn pub-type="epub">1476-4598</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1476-4598-7-49</article-id><article-id pub-id-type="pmid">18533032</article-id><article-id pub-id-type="doi">10.1186/1476-4598-7-49</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Meta-analysis of human cancer microarrays reveals GATA3 is integral to the estrogen receptor alpha pathway</article-title></title-group><contrib-group><contrib id="A1" contrib-type="author"><name><surname>Wilson</surname><given-names>Brian J</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>brian.wilson2@mcgill.ca</email></contrib><contrib id="A2" corresp="yes" contrib-type="author"><name><surname>Gigu&#x000e8;re</surname><given-names>Vincent</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>vincent.giguere@mcgill.ca</email></contrib></contrib-group><aff id="I1"><label>1</label>Molecular Oncology Group, Room H5-45, McGill University Health Centre, 687 Pine Avenue West, Montr&#x000e9;al, Qu&#x000e9;bec, H3A 1A1, Canada</aff><pub-date pub-type="collection"><year>2008</year></pub-date><pub-date pub-type="epub"><day>4</day><month>6</month><year>2008</year></pub-date><volume>7</volume><fpage>49</fpage><lpage>49</lpage><ext-link ext-link-type="uri" xlink:href="http://www.molecular-cancer.com/content/7/1/49"/><history><date date-type="received"><day>28</day><month>11</month><year>2007</year></date><date date-type="accepted"><day>4</day><month>6</month><year>2008</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2008 Wilson and Gigu&#x000e8;re; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2008</copyright-year><copyright-holder>Wilson and Gigu&#x000e8;re; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Wilson J Brian brian.wilson2@mcgill.ca </dc:author><dc:title> Meta-analysis of human cancer microarrays reveals GATA3 is integral to the estrogen receptor alpha pathway </dc:title><dc:date>2008</dc:date><dcterms:bibliographicCitation>Molecular Cancer 7(1): 49-. (2008)</dcterms:bibliographicCitation><dc:identifier type="sici">1476-4598(2008)7:1&#x0003c;49&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1476-4598</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>The transcription factor GATA3 has recently been shown to be necessary for mammary gland morphogenesis and luminal cell differentiation. There is also an increasing body of data linking GATA3 to the estrogen receptor &#x003b1; (ER&#x003b1;) pathway. Among these it was shown that GATA3 associates with the promoter of the ER&#x003b1; gene and ER&#x003b1; can reciprocally associate with the GATA3 gene. GATA3 has also been directly implicated in a differentiated phenotype in mouse models of mammary tumourigenesis. The purpose of our study was to compare coexpressed genes, by meta-analysis, of GATA3 and relate these to a similar analysis for ER&#x003b1; to determine the depth of overlap.</p></sec><sec><title>Results</title><p>We have used a newly described method of meta-analysis of multiple cancer studies within the Oncomine database, focusing here predominantly upon breast cancer studies. We demonstrate that ER&#x003b1; and GATA3 reciprocally have the highest overlap with one another. Furthermore, we show that when both coexpression meta-analysis lists for ER&#x003b1; and GATA3 are compared there is a significant overlap between both and, like ER&#x003b1;, GATA3 coexpresses with ER&#x003b1; pathway partners such as pS2 (<italic>TFF1</italic>), <italic>TFF3</italic>, <italic>FOXA1</italic>, <italic>BCL2</italic>, <italic>ERBB4</italic>, <italic>XBP1</italic>, <italic>NRIP1</italic>, <italic>IL6ST</italic>, keratin 18(<italic>KRT18</italic>) and cyclin D1 (<italic>CCND1</italic>). Moreover, as these data are derived from human tumour samples this adds credence to previous cell-culture or murine based studies.</p></sec><sec><title>Conclusion</title><p>GATA3 is hypothesized to be integral to the ER&#x003b1; pathway given the following: (1) The large overlap of coexpressed genes as seen by meta-analysis, between GATA3 and ER&#x003b1;, (2) The highest coexpressing gene for GATA3 was ER&#x003b1; and <italic>vice-versa</italic>, (3) GATA3, like ER&#x003b1;, coexpresses with many well-known ER&#x003b1; pathway partners such as pS2.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>While GATA3 has most intensively been studied in the immune system [<xref ref-type="bibr" rid="B1">1</xref>] GATA3 is also expressed in other biological environments such as the human endometrium epithelial cells, where levels are regulated in a cyclic manner [<xref ref-type="bibr" rid="B2">2</xref>]. GATA3 levels are also considered a good prognostic biomarker in breast tumours. Specifically, in the luminal A subtype of breast cancer GATA3 has both a favorable prognostic outcome, and the highest ER&#x003b1; and GATA3 expression of all breast tumours [<xref ref-type="bibr" rid="B3">3</xref>]. Consistent with this, basal-like tumours have the lowest GATA3 expression and the worst prognosis. GATA3 has also been shown in murine models to be essential to the development and maintenance of mammary luminal cells [<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B5">5</xref>]. There is also tentative data showing that different polymorphisms of the GATA3 gene may associate with differential susceptibility to breast cancer [<xref ref-type="bibr" rid="B6">6</xref>].</p><p>GATA3 levels have previously been correlated with expression of ER&#x003b1; [<xref ref-type="bibr" rid="B7">7</xref>] and both were shown to reciprocally regulate one another at the transcriptional level in a cell-culture based system in a cross-regulatory loop [<xref ref-type="bibr" rid="B8">8</xref>]. Furthermore, in a meta-analysis of ER&#x003b1; 10 genes were proposed as classifier of ER&#x003b1; positive breast tumours, listing GATA3 as one of these [<xref ref-type="bibr" rid="B9">9</xref>]. A study has also compared microarray experiments between estradiol-induced genes from MCF-7 cells, and transfected GATA3-induced genes from 293T cells to assess common upregulated genes [<xref ref-type="bibr" rid="B10">10</xref>].</p><p>In an elegant series of experiments utilizing MMTV-PyMT (polyoma middle T antigen) mice it was first shown that GATA3 expression was downregulated with the transition from adenoma to carcinoma in mammary tumours, and the expression was lost in lung metastases. Infection of the MMTV-PyMT carcinomas with GATA3 upregulated markers of differentiation and resulted in a dramatic 27-fold reduction in lung metasases [<xref ref-type="bibr" rid="B11">11</xref>]. Further crossing of these mice with an inducible cre-WAP (whey acidic protein &#x02013; specific to luminal mammary epithelial cells) driven knockout of <italic>GATA3</italic>, resulted in loss of markers of terminal differentiation, detachment from the basal membrane and apoptosis. This is consistent with the requirement of GATA3 in differentiated tumours.</p><p>As described in a recent study known pathway partners have been shown to yield a similar 'meta-analysis coexpression signature' i.e. having a significant overlap of coexpressed genes can link proteins to the same pathways [<xref ref-type="bibr" rid="B12">12</xref>]. Thus performing independent meta-analyses for ER&#x003b1; and GATA3 (putative pathway partners), then comparing the results for overlapping genes would yield a highly significant number of genes if these transcription factors were in the same pathway. We report here not only that these meta-analyses have a high degree of overlap, but that genes identified are consistent with previous reports of the ER&#x003b1; pathway regulation. Additionally we show this correlation with previously identified ER&#x003b1; target genes by combining our meta-analysis data with both RT-PCR and genome-wide location analysis from other studies. These data not only confirm GATA3 as being a key player in the ER&#x003b1; pathway, but also give fresh insights into the pathway itself.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Meta-analysis</title><p>The following procedure was undertaken for independent meta-analyses of GATA3 or ER&#x003b1;: a co-expression gene search was performed within Oncomine [<xref ref-type="bibr" rid="B13">13</xref>]. Twenty-one studies were chosen for analysis, most of which were breast cancer studies. The top 400 coexpressed genes were extracted and filtered to give one representative gene per study (removing duplicates and ESTs). These filtered genelists were then compared for repeating coexpressed genes over multiple studies. The frequency cutoff was 3 studies (14% of 21 studies). This generated a meta-analysis list for ER&#x003b1; or GATA3, which were then compared for overlap. As the overlap was high the stringency was increased to 4 studies (19%), the data of which is used for Table <xref ref-type="table" rid="T1">1</xref>. Gene names were obtained using Genecards [<xref ref-type="bibr" rid="B14">14</xref>].</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Overlapping meta-analyses of GATA3 and ER&#x003b1; at cutoff of 4 studies (19%)</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left" colspan="4"><bold>Overlap of ER&#x003b1; and GATA3 (4 or more studies)</bold></td></tr><tr><td align="left" colspan="4">ER&#x003b1; = 257, GATA3 = 194, OVERLAP = 108</td></tr><tr><td></td><td align="right"><bold>ER&#x003b1;</bold></td><td align="right"><bold>GATA3</bold></td><td></td></tr></thead><tbody><tr><td align="left">GATA3</td><td align="right"><bold>48%</bold></td><td align="right">100%</td><td align="left">GATA binding protein 3</td></tr><tr><td align="left">ESR1</td><td align="right">100%</td><td align="right"><bold>67%</bold></td><td align="left">estrogen receptor 1 (estrogen receptor alpha)</td></tr><tr><td align="left">XBP1</td><td align="right"><bold>38%</bold></td><td align="right"><bold>52%</bold></td><td align="left">X-box binding protein 1</td></tr><tr><td align="left">FOXA1</td><td align="right"><bold>33%</bold></td><td align="right"><bold>52%</bold></td><td align="left">forkhead box A1</td></tr><tr><td align="left">FOXC1</td><td align="right">19%</td><td align="right">24%</td><td align="left">forkhead box C1</td></tr><tr><td align="left">TFF1</td><td align="right"><bold>33%</bold></td><td align="right"><bold>52%</bold></td><td align="left">trefoil factor 1 (breast cancer, estrogen-inducible sequence expressed in) [pS2]</td></tr><tr><td align="left">TFF3</td><td align="right"><bold>38%</bold></td><td align="right"><bold>67%</bold></td><td align="left">trefoil factor 3 (intestinal)</td></tr><tr><td align="left">NRIP1</td><td align="right">19%</td><td align="right">19%</td><td align="left">nuclear receptor interacting protein 1 (RIP140)</td></tr><tr><td align="left">BCL2</td><td align="right"><bold>43%</bold></td><td align="right"><bold>67%</bold></td><td align="left">B-cell CLL/lymphoma 2</td></tr><tr><td align="left">ACADSB</td><td align="right"><bold>38%</bold></td><td align="right"><bold>48%</bold></td><td align="left">acyl-Coenzyme A dehydrogenase, short/branched chain</td></tr><tr><td align="left">LAF4</td><td align="right"><bold>43%</bold></td><td align="right"><bold>38%</bold></td><td align="left">lymphoid nuclear protein related to AF4</td></tr><tr><td align="left">COX6C</td><td align="right"><bold>38%</bold></td><td align="right"><bold>33%</bold></td><td align="left">cytochrome c oxidase subunit VIc</td></tr><tr><td align="left">FBP1</td><td align="right"><bold>38%</bold></td><td align="right"><bold>33%</bold></td><td align="left">fructose-1,6-bisphosphatase 1</td></tr><tr><td align="left">IGF1R</td><td align="right"><bold>38%</bold></td><td align="right"><bold>33%</bold></td><td align="left">insulin-like growth factor 1 receptor</td></tr><tr><td align="left">IRS1</td><td align="right"><bold>33%</bold></td><td align="right"><bold>33%</bold></td><td align="left">insulin receptor substrate 1</td></tr><tr><td align="left">CELSR2</td><td align="right"><bold>38%</bold></td><td align="right"><bold>38%</bold></td><td align="left">cadherin, EGF LAG seven-pass G-type receptor 2 (flamingo homolog, Drosophila)</td></tr><tr><td align="left">LRBA</td><td align="right"><bold>38%</bold></td><td align="right"><bold>38%</bold></td><td align="left">LPS-responsive vesicle trafficking, beach and anchor containing</td></tr><tr><td align="left">NAT1</td><td align="right"><bold>33%</bold></td><td align="right"><bold>57%</bold></td><td align="left">N-acetyltransferase 1 (arylamine N-acetyltransferase)</td></tr><tr><td align="left">SCNN1A</td><td align="right"><bold>38%</bold></td><td align="right"><bold>57%</bold></td><td align="left">sodium channel, nonvoltage-gated 1 alpha</td></tr><tr><td align="left">DNAJC12</td><td align="right"><bold>33%</bold></td><td align="right"><bold>48%</bold></td><td align="left">DnaJ (Hsp40) homolog, subfamily C, member 12</td></tr><tr><td align="left">RAB31</td><td align="right"><bold>38%</bold></td><td align="right">19%</td><td align="left">RAB31, member RAS oncogene family</td></tr><tr><td align="left">RABEP1</td><td align="right"><bold>33%</bold></td><td align="right"><bold>43%</bold></td><td align="left">rabaptin, RAB GTPase binding effector protein 1</td></tr><tr><td align="left">SELENBP1</td><td align="right"><bold>33%</bold></td><td align="right"><bold>33%</bold></td><td align="left">selenium binding protein 1</td></tr><tr><td align="left">FAAH</td><td align="right"><bold>38%</bold></td><td align="right"><bold>33%</bold></td><td align="left">fatty acid amide hydrolase</td></tr><tr><td align="left">TNFSF10</td><td align="right"><bold>38%</bold></td><td align="right"><bold>33%</bold></td><td align="left">tumor necrosis factor (ligand) superfamily, member 10</td></tr><tr><td align="left">SLC22A18</td><td align="right"><bold>33%</bold></td><td align="right">24%</td><td align="left">solute carrier family 22 (organic cation transporter), member 1</td></tr><tr><td align="left">SLC39A6</td><td align="right"><bold>38%</bold></td><td align="right"><bold>57%</bold></td><td align="left">solute carrier family 39 (zinc transporter), member 6 (Estrogen regulated protein LIV-1)</td></tr><tr><td align="left">SLC40A1</td><td align="right"><bold>33%</bold></td><td align="right">19%</td><td align="left">solute carrier family 40 (iron-regulated transporter), member 1</td></tr><tr><td align="left">SLC9A3R1</td><td align="right">19%</td><td align="right"><bold>43%</bold></td><td align="left">solute carrier family 9 (sodium/hydrogen exchanger), isoform 3 regulator 1</td></tr><tr><td align="left">SIAH2</td><td align="right"><bold>33%</bold></td><td align="right"><bold>33%</bold></td><td align="left">seven in absentia homolog 2 (Drosophila)</td></tr><tr><td align="left">SERPINA3</td><td align="right"><bold>38%</bold></td><td align="right">24%</td><td align="left">serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3</td></tr><tr><td align="left">SERPINA5</td><td align="right"><bold>33%</bold></td><td align="right">19%</td><td align="left">serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), 5</td></tr><tr><td align="left">SERPINA6</td><td align="right">19%</td><td align="right">24%</td><td align="left">serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), 6</td></tr><tr><td align="left">ERBB3</td><td align="right"><bold>33%</bold></td><td align="right">19%</td><td align="left">v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian)</td></tr><tr><td align="left">ERBB4</td><td align="right">19%</td><td align="right"><bold>48%</bold></td><td align="left">v-erb-a erythroblastic leukemia viral oncogene homolog 4 (avian)</td></tr><tr><td align="left">IL6ST</td><td align="right">24%</td><td align="right"><bold>38%</bold></td><td align="left">interleukin 6 signal transducer (gp130, oncostatin M receptor)</td></tr><tr><td align="left">KIAA0040</td><td align="right">24%</td><td align="right">24%</td><td align="left">KIAA0040 protein</td></tr><tr><td align="left">KIAA0303</td><td align="right"><bold>33%</bold></td><td align="right"><bold>43%</bold></td><td align="left">Similar to Mouse serine/threonine protein kinase MAST205</td></tr><tr><td align="left">KIAA0882</td><td align="right">19%</td><td align="right">19%</td><td align="left">KIAA0882 protein</td></tr><tr><td align="left">ITPR1</td><td align="right">24%</td><td align="right"><bold>33%</bold></td><td align="left">inositol 1,4,5-triphosphate receptor, type 1</td></tr><tr><td align="left">INPP4B</td><td align="right">24%</td><td align="right"><bold>43%</bold></td><td align="left">inositol polyphosphate-4-phosphatase, type II, 105kDa</td></tr><tr><td align="left">JMJD2B</td><td align="right">24%</td><td align="right"><bold>48%</bold></td><td align="left">jumonji domain containing 2B</td></tr><tr><td align="left">C10orf116</td><td align="right">24%</td><td align="right"><bold>52%</bold></td><td align="left">chromosome 10 open reading frame 116</td></tr><tr><td align="left">ANXA9</td><td align="right">19%</td><td align="right"><bold>43%</bold></td><td align="left">annexin A9</td></tr><tr><td align="left">AR</td><td align="right">19%</td><td align="right"><bold>33%</bold></td><td align="left">androgen receptor (dihydrotestosterone receptor; Kennedy disease)</td></tr><tr><td align="left">CCND1</td><td align="right">19%</td><td align="right"><bold>48%</bold></td><td align="left">cyclin D1 (PRAD1: parathyroid adenomatosis 1)</td></tr><tr><td align="left">CCNG2</td><td align="right">19%</td><td align="right">24%</td><td align="left">cyclin G2</td></tr><tr><td align="left">CA12</td><td align="right">19%</td><td align="right"><bold>38%</bold></td><td align="left">carbonic anhydrase XII</td></tr><tr><td align="left">CACNA1D</td><td align="right">19%</td><td align="right"><bold>33%</bold></td><td align="left">calcium channel, voltage-dependent, L type, alpha 1D subunit</td></tr><tr><td align="left">CACNA2D2</td><td align="right">19%</td><td align="right"><bold>43%</bold></td><td align="left">calcium channel, voltage-dependent, alpha 2/delta subunit 2</td></tr><tr><td align="left">DNALI1</td><td align="right">24%</td><td align="right"><bold>43%</bold></td><td align="left">dynein, axonemal, light intermediate polypeptide 1</td></tr><tr><td align="left">AGR2</td><td align="right">19%</td><td align="right"><bold>33%</bold></td><td align="left">anterior gradient 2 homolog (Xenepus laevis)</td></tr><tr><td align="left">GFRA1</td><td align="right">33%</td><td align="right"><bold>48%</bold></td><td align="left">GDNF family receptor alpha 1</td></tr><tr><td align="left">HPN</td><td align="right">19%</td><td align="right"><bold>43%</bold></td><td align="left">hepsin (transmembrane protease, serine 1)</td></tr><tr><td align="left">GREB1</td><td align="right">19%</td><td align="right"><bold>38%</bold></td><td align="left">GREB1 protein</td></tr><tr><td align="left">MAPT</td><td align="right">19%</td><td align="right"><bold>38%</bold></td><td align="left">microtubule-associated protein tau</td></tr><tr><td align="left">MLPH</td><td align="right">24%</td><td align="right"><bold>33%</bold></td><td align="left">melanophilin</td></tr><tr><td align="left">KRT18</td><td align="right">24%</td><td align="right"><bold>33%</bold></td><td align="left">keratin 18</td></tr><tr><td align="left">PTPRT</td><td align="right">24%</td><td align="right"><bold>48%</bold></td><td align="left">protein tyrosine phosphatase, receptor type, T</td></tr><tr><td align="left">STC2</td><td align="right">24%</td><td align="right"><bold>33%</bold></td><td align="left">stanniocalcin 2</td></tr><tr><td align="left">SCUBE2</td><td align="right"><bold>33%</bold></td><td align="right">24%</td><td align="left">CEGP1 protein</td></tr><tr><td align="left">PTGER3</td><td align="right"><bold>33%</bold></td><td align="right">24%</td><td align="left">prostaglandin E receptor 3 (subtype EP3)</td></tr><tr><td align="left">PDCD4</td><td align="right"><bold>33%</bold></td><td align="right">24%</td><td align="left">programmed cell death 4 (neoplastic transformation inhibitor)</td></tr><tr><td align="left">MUC1</td><td align="right"><bold>33%</bold></td><td align="right">29%</td><td align="left">mucin 1, transmembrane</td></tr><tr><td align="left">NPY1R</td><td align="right"><bold>33%</bold></td><td align="right">29%</td><td align="left">neuropeptide Y receptor Y1</td></tr><tr><td align="left">FLJ20366</td><td align="right"><bold>38%</bold></td><td align="right">24%</td><td align="left">hypothetical protein FLJ20366</td></tr><tr><td align="left">TLE3</td><td align="right"><bold>33%</bold></td><td align="right">29%</td><td align="left">transducin-like enhancer of split 3 (E(sp1) homolog, Drosophila)</td></tr><tr><td align="left">13CDNA73</td><td align="right">24%</td><td align="right">29%</td><td align="left">hypothetical protein CG003</td></tr><tr><td align="left">AGTR1</td><td align="right">24%</td><td align="right">29%</td><td align="left">Angiotensin II receptor, type 1</td></tr><tr><td align="left">ASAH1</td><td align="right">24%</td><td align="right">29%</td><td align="left">N-acylsphingosine amidohydrolase (acid ceramidase) 1</td></tr><tr><td align="left">BF</td><td align="right">24%</td><td align="right">24%</td><td align="left">B-factor, properdin</td></tr><tr><td align="left">ENPP1</td><td align="right">24%</td><td align="right">29%</td><td align="left">ectonucleotide pyrophosphatase/phosphodiesterase 1</td></tr><tr><td align="left">QDPR</td><td align="right">24%</td><td align="right">29%</td><td align="left">quinoid dihydropteridine reductase</td></tr><tr><td align="left">C9orf116</td><td align="right">19%</td><td align="right">29%</td><td align="left">chromosome 9 open reading frame 116</td></tr><tr><td align="left">CYFIP2</td><td align="right">19%</td><td align="right">29%</td><td align="left">cytoplasmic FMR1 interacting protein 2</td></tr><tr><td align="left">GRIA2</td><td align="right">19%</td><td align="right">29%</td><td align="left">glutamate receptor, ionotropic, AMPA 2</td></tr><tr><td align="left">GSTM3</td><td align="right">19%</td><td align="right">29%</td><td align="left">Glutathione S-transferase M3 (brain)</td></tr><tr><td align="left">ACOX2</td><td align="right">19%</td><td align="right">29%</td><td align="left">acyl-Coenzyme A oxidase 2, branched chain</td></tr><tr><td align="left">LRIG1</td><td align="right">19%</td><td align="right">29%</td><td align="left">leucine-rich repeats and immunoglobulin-like domains 1</td></tr><tr><td align="left">PLAT</td><td align="right">19%</td><td align="right">29%</td><td align="left">plasminogen activator, tissue</td></tr><tr><td align="left">MAGED2</td><td align="right">19%</td><td align="right">29%</td><td align="left">Melanoma antigen family D, 2</td></tr><tr><td align="left">THRAP2</td><td align="right">19%</td><td align="right">29%</td><td align="left">thyroid hormone receptor associated protein 2</td></tr><tr><td align="left">MSX2</td><td align="right">24%</td><td align="right">24%</td><td align="left">msh homeo box homolog 2 (Drosophila)</td></tr><tr><td align="left">UGCG</td><td align="right">24%</td><td align="right">24%</td><td align="left">UDP-glucose ceramide glucosyltransferase</td></tr><tr><td align="left">ALCAM</td><td align="right">19%</td><td align="right">24%</td><td align="left">activated leukocyte cell adhesion molecule</td></tr><tr><td align="left">ALDH4A1</td><td align="right">19%</td><td align="right">24%</td><td align="left">aldehyde dehydrogenase 4 family, member A1</td></tr><tr><td align="left">ABCA3</td><td align="right">24%</td><td align="right">19%</td><td align="left">ATP-binding cassette, sub-family A (ABC1), member 3</td></tr><tr><td align="left">LOC51760</td><td align="right">19%</td><td align="right">24%</td><td align="left">B/K protein</td></tr><tr><td align="left">PRSS23</td><td align="right">19%</td><td align="right">24%</td><td align="left">protease, serine, 23</td></tr><tr><td align="left">RHOH</td><td align="right">24%</td><td align="right">19%</td><td align="left">ras homolog gene family, member H</td></tr><tr><td align="left">TFAP2B</td><td align="right">19%</td><td align="right">24%</td><td align="left">transcription factor AP-2 beta (activating enhancer binding protein 2 beta)</td></tr><tr><td align="left">WFDC2</td><td align="right">24%</td><td align="right">19%</td><td align="left">WAP four-disulfide core domain 2</td></tr><tr><td align="left">ANGPTL1</td><td align="right">19%</td><td align="right">19%</td><td align="left">angiopoietin-like 1</td></tr><tr><td align="left">BCAS1</td><td align="right">19%</td><td align="right">19%</td><td align="left">breast carcinoma amplified sequence 1</td></tr><tr><td align="left">CYP2B6</td><td align="right">19%</td><td align="right">19%</td><td align="left">cytochrome P450, subfamily IIB (phenobarbital-inducible), polypeptide 6</td></tr><tr><td align="left">EML2</td><td align="right">19%</td><td align="right">19%</td><td align="left">echinoderm microtubule associated protein like 2</td></tr><tr><td align="left">FLNB</td><td align="right">19%</td><td align="right">19%</td><td align="left">filamin B, beta (actin binding protein 278)</td></tr><tr><td align="left">GPR160</td><td align="right">19%</td><td align="right">19%</td><td align="left">G protein-coupled receptor 160</td></tr><tr><td align="left">LU</td><td align="right">19%</td><td align="right">19%</td><td align="left">Lutheran blood group (Auberger b antigen included)</td></tr><tr><td align="left">MRPS30</td><td align="right">19%</td><td align="right">19%</td><td align="left">mitochondrial ribosomal protein S30</td></tr><tr><td align="left">PTE2B</td><td align="right">19%</td><td align="right">19%</td><td align="left">peroxisomal acyl-CoA thioesterase 2B</td></tr><tr><td align="left">RERG</td><td align="right">19%</td><td align="right">19%</td><td align="left">RAS-like, estrogen-regulated, growth inhibitor</td></tr><tr><td align="left">RNASE4</td><td align="right">19%</td><td align="right">19%</td><td align="left">ribonuclease, RNase A family, 4</td></tr><tr><td align="left">RNF110</td><td align="right">19%</td><td align="right">19%</td><td align="left">polycomb group ring finger 2 (MEL-18)</td></tr><tr><td align="left">SEMA3C</td><td align="right">19%</td><td align="right">19%</td><td align="left">sema domain, immunoglobulin domain (Ig), short basic domain, (semaphorin) 3C</td></tr><tr><td align="left">SULT2B1</td><td align="right">19%</td><td align="right">19%</td><td align="left">sulfotransferase family, cytosolic, 2B, member 1</td></tr><tr><td align="left">TPBG</td><td align="right">19%</td><td align="right">19%</td><td align="left">trophoblast glycoprotein</td></tr><tr><td align="left">TPD52</td><td align="right">19%</td><td align="right">19%</td><td align="left">tumor protein D52</td></tr><tr><td align="left">KAL1</td><td align="right">19%</td><td align="right">19%</td><td align="left">Kallmann syndrome 1 sequence</td></tr></tbody></table><table-wrap-foot><p>After individual Oncomine meta-analysis of 21 studies both lists of coexpressing genes, for GATA3 and ER&#x003b1; were compared for overlap. Overlap greater than 30% frequency (7 studies) is shown in <bold>bold</bold>. Overlap list is arranged by percent frequency.</p></table-wrap-foot></table-wrap></sec><sec><title>Reporter gene assays</title><p>MCF-7 Cells were grown in DMEM (minus phenol-red) with 10% charcoal-stripped FBS. SKBR3 were grown in DMEM with 10% FBS. <italic>MUC1 </italic>(-881 to +13) was cloned as a KpnI/XhoI fragment, and <italic>KRT18 </italic>(-2961 to +96) was cloned as a KpnI/BglII fragment. Both were generated by high-fidelity PCR from human genomic DNA (Roche), and were ligated into pGL4.20 (Promega). pS2 reporter has previously been described [<xref ref-type="bibr" rid="B15">15</xref>]. Luciferase reporter gene assays were performed using standard protocols. Here 200&#x02013;400 ng reporter were transfected with 200 ng pcDNA3 or pcDNA3-GATA3, and 3U/well of &#x003b2;-galactosidase protein (Sigma) as transfection efficiency control. Ten nM Tamoxifen (Sigma) was incubated for 14 h prior to cell assay.</p></sec></sec><sec><title>Results and Discussion</title><p>Using the Oncomine&#x02122; integrated cancer profiling database GATA3 and ER&#x003b1; were searched for coexpressing genes [<xref ref-type="bibr" rid="B13">13</xref>]. Coexpression data from 21 multi-array studies was extracted and analysed, separately for ER&#x003b1; and GATA3. While these studies varied in cancer-types, the overwhelming majority extracted for analysis were breast-cancer based [Additional file <xref ref-type="supplementary-material" rid="S1">1</xref> and <xref ref-type="supplementary-material" rid="S2">2</xref>]. The frequency of coexpressing genes over the 21 studies was determined and the cutoff set to 3 studies or more (3 studies = 14% frequency overlap &#x02013; [see Additional file <xref ref-type="supplementary-material" rid="S1">1</xref> and <xref ref-type="supplementary-material" rid="S2">2</xref>]). Next, to ascertain the extent GATA3 may play a role in ER&#x003b1; pathways the frequency coexpression lists were compared for overlap. Interestingly, there was an extensive overlap between both GATA3 and ER&#x003b1; lists at the cutoff of 3 studies (Figure <xref ref-type="fig" rid="F1">1A</xref>). Increasing the cutoff to 4 or more studies (almost one-fifth of the studies) did not change the relative overlap with respect to total gene numbers, with 43% of the number of ER&#x003b1; coexpressed genes, and 56% of GATA3 coexpressed genes represented in the overlap (Figure <xref ref-type="fig" rid="F1">1B</xref>). The overlap data with the frequency cutoff of 4 studies is shown in Table <xref ref-type="table" rid="T1">1</xref>.</p><fig position="float" id="F1"><label>Figure 1</label><caption><p><bold>Venn diagram showing overlap between ER&#x003b1; and GATA3 meta-analyses</bold>. (A) Overlap when the frequency cutoff is 3 studies (14%). (B) Overlap when the frequency cutoff is 4 studies (19%).</p></caption><graphic xlink:href="1476-4598-7-49-1"/></fig><p>Every technique has its caveats, and the limitation here is that we are assessing the common genes that are consistently coexpressed with ER&#x003b1; and GATA3 over many different human cancer studies. This implies that coexpressed genes are in the same pathways as GATA3 and ER&#x003b1;. However, the meta-analyses can only infer association within the same pathways, and pathway coexpression at the RNA level might not necessarily translate into protein level. Nevertheless, our data are strongly supported by previous knowledge of the ER&#x003b1; pathway.</p><p>A recent study identified 51 genes significantly upregulated in ER&#x003b1; positive breast tumours, using a real-time PCR based approach [<xref ref-type="bibr" rid="B16">16</xref>]. Attesting to the stringency of the meta-analysis approach used here 32 of theses genes were found to overlap with the ER&#x003b1; coexpression list, while an identical number also overlapped with GATA3 (Table <xref ref-type="table" rid="T2">2</xref>). This was reflected in a similar study comparing ER&#x003b1; over-expressed transcripts in both oligonucleotide microarray and SAGE platforms [<xref ref-type="bibr" rid="B17">17</xref>], where 27 genes common to the ER&#x003b1; pathway are represented here in our common ER&#x003b1;:GATA3 meta-analysis comparison [see Additional file <xref ref-type="supplementary-material" rid="S3">3</xref>]. These data not only acted as wide-ranging external validation for the individual meta-analyses, but also confirmed the extent of the involvement of GATA3 in ER&#x003b1; pathways.</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Comparison of GATA3 and ER&#x003b1; meta-analyses, and RT-PCR study</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="center"><bold>GATA3 Oncomine</bold></td><td align="center"><bold>ER&#x003b1; Oncomine</bold></td></tr></thead><tbody><tr><td align="left">ESR1</td><td align="center">&#x02714;</td><td align="center">&#x02714;</td></tr><tr><td align="left">GATA3</td><td align="center">&#x02714;</td><td align="center">&#x02714;</td></tr><tr><td align="left">TFF1</td><td align="center">&#x02714;</td><td align="center">&#x02714;</td></tr><tr><td align="left">TFF3</td><td align="center">&#x02714;</td><td align="center">&#x02714;</td></tr><tr><td align="left">FOXA1</td><td align="center">&#x02714;</td><td align="center">&#x02714;</td></tr><tr><td align="left">XBP1</td><td align="center">&#x02714;</td><td align="center">&#x02714;</td></tr><tr><td align="left">IL6ST</td><td align="center">&#x02714;</td><td align="center">&#x02714;</td></tr><tr><td align="left">KRT18</td><td align="center">&#x02714;</td><td align="center">&#x02714;</td></tr><tr><td align="left">AR</td><td align="center">&#x02714;</td><td align="center">&#x02714;</td></tr><tr><td align="left">BCL2</td><td align="center">&#x02714;</td><td align="center">&#x02714;</td></tr><tr><td align="left">CCND1</td><td align="center">&#x02714;</td><td align="center">&#x02714;</td></tr><tr><td align="left">RERG</td><td align="center">&#x02714;</td><td align="center">&#x02714;</td></tr><tr><td align="left">ERBB4</td><td align="center">&#x02714;</td><td align="center">&#x02714;</td></tr><tr><td align="left">NAT1</td><td align="center">&#x02714;</td><td align="center">&#x02714;</td></tr><tr><td align="left">SLC39A6</td><td align="center">&#x02714;</td><td align="center">&#x02714;</td></tr><tr><td align="left">DNAJC12</td><td align="center">&#x02714;</td><td align="center">&#x02714;</td></tr><tr><td align="left">HPN</td><td align="center">&#x02714;</td><td align="center">&#x02714;</td></tr><tr><td align="left">CYP2B6</td><td align="center">&#x02714;</td><td align="center">&#x02714;</td></tr><tr><td align="left">CA12</td><td align="center">&#x02714;</td><td align="center">&#x02714;</td></tr><tr><td align="left">STC2</td><td align="center">&#x02714;</td><td align="center">&#x02714;</td></tr><tr><td align="left">ACADSB</td><td align="center">&#x02714;</td><td align="center">&#x02714;</td></tr><tr><td align="left">LRBA</td><td align="center">&#x02714;</td><td align="center">&#x02714;</td></tr><tr><td align="left">PTPRT</td><td align="center">&#x02714;</td><td align="center">&#x02714;</td></tr><tr><td align="left">SULT2B1</td><td align="center">&#x02714;</td><td align="center">&#x02714;</td></tr><tr><td align="left">MYB</td><td align="center">&#x02714;</td><td align="center">&#x02714;</td></tr><tr><td align="left">SEMA3B</td><td align="center">&#x02714;</td><td align="center">&#x02714;</td></tr><tr><td align="left">RET</td><td align="center">&#x02714;</td><td align="center">&#x02714;</td></tr><tr><td align="left">SLC7A2</td><td align="center">&#x02714;</td><td align="center">&#x02714;</td></tr><tr><td align="left">RABEP1</td><td align="center">&#x02714;</td><td></td></tr><tr><td align="left">IGFBP4</td><td align="center">&#x02714;</td><td></td></tr><tr><td align="left">CGA</td><td align="center">&#x02714;</td><td></td></tr><tr><td align="left">GJA1</td><td align="center">&#x02714;</td><td></td></tr><tr><td align="left">PGR</td><td></td><td align="center">&#x02714;</td></tr><tr><td align="left">RARRES</td><td></td><td align="center">&#x02714;</td></tr><tr><td align="left">BBC3</td><td></td><td align="center">&#x02714;</td></tr><tr><td align="left">LOC255743</td><td></td><td align="center">&#x02714;</td></tr></tbody></table><table-wrap-foot><p>51 genes were identified as being upregulated in ER&#x003b1;-positive breast tumours in a recent study by Tozlu <italic>et al</italic>, and are compared with the Oncomine meta-analysis lists for ER&#x003b1; and GATA3, showing a significant overlap. &#x02714; shows that this gene is represented.</p></table-wrap-foot></table-wrap><p>Furthermore, when compared to a list of genome-wide promoters shown to be bound by ER&#x003b1; in MCF-7 cells [<xref ref-type="bibr" rid="B18">18</xref>] or on chromosomes 21 and 22 [<xref ref-type="bibr" rid="B19">19</xref>], 23 were identified in the ER&#x003b1; meta-analysis list, while 27 were identified within the GATA3 list (Table <xref ref-type="table" rid="T3">3</xref>). This again supports both the validity of the meta-analysis technique used here, and the role of GATA3 in ER&#x003b1; pathways. It is also possible that the overlap would be even higher if the ER&#x003b1; genomic location analysis were performed on a pool of human ER&#x003b1;-positive breast tumour samples as opposed to a cell-culture model system. While not to detract from the power of a model system such as MCF-7 there are likely to be a great many differences between a homogeneous cell monolayer and a 3-dimensional cancer made up of a heterogeneous cell population.</p><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Comparison of GATA3 and ER&#x003b1; meta-analyses with previously reported binding sites (by ChIP-chip analysis)</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>ER&#x003b1; ChIP-chip: GATA3 Oncomine</bold></td><td align="left"><bold>ER&#x003b1; ChIP-chip: ER&#x003b1; Oncomine</bold></td></tr></thead><tbody><tr><td align="left"><bold>ABCA3</bold></td><td align="left"><bold>ABCA3</bold></td></tr><tr><td align="left">ALDH3B2</td><td align="left"><bold>ANXA9</bold></td></tr><tr><td align="left"><bold>ANXA9</bold></td><td align="left">BTRC</td></tr><tr><td align="left">EPS8</td><td align="left">C2</td></tr><tr><td align="left"><bold>ESR1</bold></td><td align="left">CYP51A1</td></tr><tr><td align="left">FLJ20152</td><td align="left"><bold>ESR1</bold></td></tr><tr><td align="left"><bold>FOXA1</bold></td><td align="left">FLJ13710</td></tr><tr><td align="left"><bold>GREB1</bold></td><td align="left"><bold>FOXA1</bold></td></tr><tr><td align="left">GTF2H2</td><td align="left"><bold>GREB1</bold></td></tr><tr><td align="left"><bold>LOC51760</bold></td><td align="left">KCNAB2</td></tr><tr><td align="left"><bold>MGC11242</bold></td><td align="left"><bold>LOC51760</bold></td></tr><tr><td align="left">MGP</td><td align="left">MB</td></tr><tr><td align="left">NAV3</td><td align="left"><bold>MGC11242</bold></td></tr><tr><td align="left">NQO1</td><td align="left">MSP</td></tr><tr><td align="left">PDZK1</td><td align="left"><bold>SEMA3B</bold></td></tr><tr><td align="left">PHF15</td><td align="left"><bold>SLC27A2</bold></td></tr><tr><td align="left">RTN1</td><td align="left"><bold>SLC7A2</bold></td></tr><tr><td align="left"><bold>SEMA3B</bold></td><td align="left">STARD10</td></tr><tr><td align="left"><bold>SLC27A2</bold></td><td align="left"><bold>STK39</bold></td></tr><tr><td align="left"><bold>SLC7A2</bold></td><td align="left"><bold>TFF1</bold></td></tr><tr><td align="left">SLC7A8</td><td align="left"><bold>TFF3</bold></td></tr><tr><td align="left"><bold>STARD10</bold></td><td align="left"><bold>NRIP1</bold></td></tr><tr><td align="left"><bold>STK39</bold></td><td align="left">RUNX1</td></tr><tr><td align="left"><bold>TFF1</bold></td><td></td></tr><tr><td align="left"><bold>TFF3</bold></td><td></td></tr><tr><td align="left">TOMM40</td><td></td></tr><tr><td align="left"><bold>NRIP1</bold></td><td></td></tr></tbody></table><table-wrap-foot><p>Oncomine meta-analysis data for GATA3 or ER&#x003b1; was compared both to a promoter list published by Laganiere <italic>et al</italic>, (P = 0.05), and to a chromosome array list of 30 genes identified by Carroll <italic>et al</italic>. The overlap is shown and common overlap between ER&#x003b1; and GATA3 is shown in <bold>bold</bold>.</p></table-wrap-foot></table-wrap><p>Of the 10 classifier genes previously identified in a meta-analysis of ER&#x003b1;, the same 4 were identified in both meta-analyses of this study (<italic>ESR1</italic>, <italic>GATA3</italic>, <italic>FOXA1</italic>, <italic>SLC39A6</italic>) [<xref ref-type="bibr" rid="B9">9</xref>]. Once again this adds credence to the high-quality data obtained in our current meta-analyses.</p><p>Implicating GATA3 in control of some of these gene products is a microarray experiment performed after overexpression of GATA3 in 293T cells [<xref ref-type="bibr" rid="B20">20</xref>]. After expression of GATA3 elevated levels of <italic>TFF1</italic>, <italic>TFF3</italic>, <italic>KRT18</italic>, <italic>FOXA1</italic>, <italic>SLC9A3R1</italic>, <italic>TPD52</italic>, <italic>BCAS1 </italic>were observed, all of which we identified here for both GATA3 and ER&#x003b1; meta-analyses. While 293T are not breast cancer cells, it raises the question of how many more of our predicted pathway partners of GATA3 would be identified if the microarray were repeated in cells such as MCF-7 which also retain high ER&#x003b1; expression. In the example of <italic>SLC9A3R1 </italic>(NHERF1) which is a putative tumour suppressor, it was shown to increase growth of 2 breast cancer cell lines when knocked down by shRNA [<xref ref-type="bibr" rid="B21">21</xref>]. If GATA3 does help to control expression of NHERF1 this might be one mechanism consistent with its role in the less-aggressive differentiated luminal A breast cancers. Another example is <italic>BCAS1 </italic>(NABC1) which is overexpressed in breast carcinomas but downregulated in colorectal tumours [<xref ref-type="bibr" rid="B22">22</xref>,<xref ref-type="bibr" rid="B23">23</xref>]. Indeed, overexpression of NABC1 did not result in changes in cell-cycle or anchorage-dependent growth properties in NIH3T3 cells, implying it may not be intrinsically oncogenic [<xref ref-type="bibr" rid="B24">24</xref>].</p><p>As GATA3 is expressed in, and regulates, luminal epithelial cells and has also been shown to regulate the <italic>MUC1 </italic>gene it is no surprise that <italic>MUC1 </italic>is also mostly expressed in luminal breast epithelial cells as well as other glandular epithelia [<xref ref-type="bibr" rid="B25">25</xref>]. <italic>MUC1</italic>, when abnormally expressed, leads to a loss of both cell-extracellular and cell-cell contacts. It has also been shown that <italic>MUC1 </italic>levels can be regulated by estrogen and ER&#x003b1; can bind putative binding sites derived from the <italic>MUC1 </italic>promoter <italic>in-vitro </italic>[<xref ref-type="bibr" rid="B26">26</xref>]. Here we reveal that both GATA3 and ER&#x003b1; coexpress with <italic>MUC1 </italic>acting as further validation of the meta-analysis technique used here. Furthermore, transfected GATA3 can activate a <italic>MUC1 </italic>promoter reporter in MCF-7 cells, even in the presence of Tamoxifen i.e. independently to ER&#x003b1; activation. This activation could be repeated in the ER&#x003b1;-negative breast cancer cell line SKBR3 (Figure <xref ref-type="fig" rid="F2">2</xref>). The activation of ER&#x003b1; pathway genes was also observed with pS2 (<italic>TFF1</italic>) and <italic>KRT18 </italic>reporters (Figure <xref ref-type="fig" rid="F2">2</xref>). These data indicate that GATA3 can have its own impact on the ER&#x003b1; pathway and is not just acting indirectly via ER&#x003b1;.</p><fig position="float" id="F2"><label>Figure 2</label><caption><p><bold>GATA3 can activate ER&#x003b1; pathway promoter reporters</bold>. GATA3 can activate MUC1, pS2, or keratin 18 promoter reporters, in ER&#x003b1;-positive MCF-7 cells (even in the presence of tamoxifen &#x02013; TAM), or in ER&#x003b1;-negative SKBR3 cells.</p></caption><graphic xlink:href="1476-4598-7-49-2"/></fig><p>It has also been postulated that, as the deletion of GATA3 in mammary primordia (by K14-Cre) resulted in an inability to form mammary placodes is similar to that of loss of LEF1, Msx1 and Msx2 these may all be intertwined in a transcriptional network [<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B27">27</xref>]. It is of interest that in our present study we observe <italic>MSX2 </italic>coexpression both with GATA3 and ER&#x003b1;, which helps to support this notion.</p><p>Using the meta-analysis data presented it is easy to build up transcriptional networks such as this and all of the data presented strongly supports (1) the quality of the meta-analysis results, (2) the concept that GATA3 is firmly entrenched within ER&#x003b1; pathways. Future in-depth analysis of the data presented may lead to novel aspects of ER&#x003b1; or GATA3 regulated pathways, and help to understand the etiology of ER&#x003b1;-positive breast cancers, and management of their outcomes.</p></sec><sec><title>Conclusion</title><p>While GATA3 has been identified previously in a meta-analysis of ER&#x003b1; only 10 genes were identified in total [<xref ref-type="bibr" rid="B9">9</xref>]. Here we give an extensive list of coexpressed ER&#x003b1; genes and for the first time a <italic>reciprocal </italic>meta-analysis for GATA3 has been performed, and the results compared for overlap. This overlap was considerable, confirming the important role of GATA3 in the ER&#x003b1; pathway. The vital question raised is whether GATA3 is crucial to the ER&#x003b1; pathway only by regulation of ER&#x003b1; levels, or through further control of ER&#x003b1;-regulated genes in concert with ER&#x003b1; itself. The GATA3 overexpression microarray experiment in 293T cells, and our reporter gene assays certainly implies the latter [<xref ref-type="bibr" rid="B20">20</xref>]. Genome-wide location analysis (ChIP-chip) of GATA3 in a well-established ER&#x003b1; system such as MCF-7 cells, as well as specific analysis of the ER&#x003b1; pathway in GATA3 conditional knockout mice will yield vital information regarding the extent that GATA3 is integral to the ER&#x003b1; pathway.</p></sec><sec><title>Authors' contributions</title><p>BW conceived and designed the study, performed the meta-analyses, the reporter assays, and wrote the manuscript. VG critically reviewed the manuscript, and approved the final version.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="S1"><caption><title>Additional file 1</title><p>GATA3 Oncomine meta-analysis. Meta-analysis results from 21 Oncomine studies shown. Coexpressing genes with GATA3 are shown with a cutoff of 3 studies (14% of the 21 studies).</p></caption><media xlink:href="1476-4598-7-49-S1.xls" mimetype="application" mime-subtype="vnd.ms-excel"><caption><p>Click here for file</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S2"><caption><title>Additional file 2</title><p>ER&#x003b1; Oncomine meta-analysis. Meta-analysis results from 21 Oncomine studies shown. Coexpressing genes with ER&#x003b1; are shown with a cutoff of 3 studies (14% of the 21 studies).</p></caption><media xlink:href="1476-4598-7-49-S2.xls" mimetype="application" mime-subtype="vnd.ms-excel"><caption><p>Click here for file</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S3"><caption><title>Additional file 3</title><p>External data comparison. Comparison of data to that of Abba <italic>et al</italic>, 2005. ER&#x003b1; pathway genes common to oligo microarrays, SAGE and our meta-analysis overlap.</p></caption><media xlink:href="1476-4598-7-49-S3.xls" mimetype="application" mime-subtype="vnd.ms-excel"><caption><p>Click here for file</p></caption></media></supplementary-material></sec></body><back><ack><sec><title>Acknowledgements</title><p>We thank John Coligan, NIH, for pcDNA3-GATA3. Funding was provided by the Canadian Institute for Cancer Research (VG) and a McGill University Health Centre fellowship (BW).</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>IC</given-names></name><name><surname>Pai</surname><given-names>SY</given-names></name></person-group><article-title>GATA-3 &#x02013; not just for Th2 cells anymore</article-title><source>Cell Mol Immunol</source><year>2007</year><volume>4</volume><fpage>15</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">17349208</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Inman</surname><given-names>D</given-names></name><name><surname>Kawana</surname><given-names>K</given-names></name><name><surname>Schust</surname><given-names>D</given-names></name><name><surname>Lininger</surname><given-names>R</given-names></name><name><surname>Young</surname><given-names>S</given-names></name></person-group><article-title>Cyclic regulation of T-Bet and GATA-3 in human endometrium</article-title><source>Reprod Sci</source><year>2008</year><volume>15</volume><fpage>83</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">18212358</pub-id><pub-id pub-id-type="doi">10.1177/1933719107309690</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mehra</surname><given-names>R</given-names></name><name><surname>Varambally</surname><given-names>S</given-names></name><name><surname>Ding</surname><given-names>L</given-names></name><name><surname>Shen</surname><given-names>R</given-names></name><name><surname>Sabel</surname><given-names>MS</given-names></name><name><surname>Ghosh</surname><given-names>D</given-names></name><name><surname>Chinnaiyan</surname><given-names>AM</given-names></name><name><surname>Kleer</surname><given-names>CG</given-names></name></person-group><article-title>Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis</article-title><source>Cancer Res</source><year>2005</year><volume>65</volume><fpage>11259</fpage><lpage>11264</lpage><pub-id pub-id-type="pmid">16357129</pub-id><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-2495</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Asselin-Labat</surname><given-names>ML</given-names></name><name><surname>Sutherland</surname><given-names>KD</given-names></name><name><surname>Barker</surname><given-names>H</given-names></name><name><surname>Thomas</surname><given-names>R</given-names></name><name><surname>Shackleton</surname><given-names>M</given-names></name><name><surname>Forrest</surname><given-names>NC</given-names></name><name><surname>Hartley</surname><given-names>L</given-names></name><name><surname>Robb</surname><given-names>L</given-names></name><name><surname>Grosveld</surname><given-names>FG</given-names></name><name><surname>Wees</surname><given-names>J van der</given-names></name><name><surname>Lindeman</surname><given-names>GJ</given-names></name><name><surname>Visvader</surname><given-names>JE</given-names></name></person-group><article-title>Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation</article-title><source>Nat Cell Biol</source><year>2007</year><volume>9</volume><fpage>201</fpage><lpage>209</lpage><pub-id pub-id-type="pmid">17187062</pub-id><pub-id pub-id-type="doi">10.1038/ncb1530</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kouros-Mehr</surname><given-names>H</given-names></name><name><surname>Slorach</surname><given-names>EM</given-names></name><name><surname>Sternlicht</surname><given-names>MD</given-names></name><name><surname>Werb</surname><given-names>Z</given-names></name></person-group><article-title>GATA-3 maintains the differentiation of the luminal cell fate in the mammary gland</article-title><source>Cell</source><year>2006</year><volume>127</volume><fpage>1041</fpage><lpage>1055</lpage><pub-id pub-id-type="pmid">17129787</pub-id><pub-id pub-id-type="doi">10.1016/j.cell.2006.09.048</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Garcia-Closas</surname><given-names>M</given-names></name><name><surname>Troester</surname><given-names>MA</given-names></name><name><surname>Qi</surname><given-names>Y</given-names></name><name><surname>Langerod</surname><given-names>A</given-names></name><name><surname>Yeager</surname><given-names>M</given-names></name><name><surname>Lissowska</surname><given-names>J</given-names></name><name><surname>Brinton</surname><given-names>L</given-names></name><name><surname>Welch</surname><given-names>R</given-names></name><name><surname>Peplonska</surname><given-names>B</given-names></name><name><surname>Gerhard</surname><given-names>DS</given-names></name><name><surname>Gram</surname><given-names>IT</given-names></name><name><surname>Kristensen</surname><given-names>V</given-names></name><name><surname>Borresen-Dale</surname><given-names>AL</given-names></name><name><surname>Chanock</surname><given-names>S</given-names></name><name><surname>Perou</surname><given-names>CM</given-names></name></person-group><article-title>Common genetic variation in GATA-binding protein 3 and differential susceptibility to breast cancer by estrogen receptor alpha tumor status</article-title><source>Cancer Epidemiol Biomarkers Prev</source><year>2007</year><volume>16</volume><fpage>2269</fpage><lpage>2275</lpage><pub-id pub-id-type="pmid">18006915</pub-id><pub-id pub-id-type="doi">10.1158/1055-9965.EPI-07-0449</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van 't Veer</surname><given-names>LJ</given-names></name><name><surname>Dai</surname><given-names>H</given-names></name><name><surname>Vijver</surname><given-names>MJ van de</given-names></name><name><surname>He</surname><given-names>YD</given-names></name><name><surname>Hart</surname><given-names>AA</given-names></name><name><surname>Mao</surname><given-names>M</given-names></name><name><surname>Peterse</surname><given-names>HL</given-names></name><name><surname>Kooy</surname><given-names>K van der</given-names></name><name><surname>Marton</surname><given-names>MJ</given-names></name><name><surname>Witteveen</surname><given-names>AT</given-names></name><name><surname>Schreiber</surname><given-names>GJ</given-names></name><name><surname>Kerkhoven</surname><given-names>RM</given-names></name><name><surname>Roberts</surname><given-names>C</given-names></name><name><surname>Linsley</surname><given-names>PS</given-names></name><name><surname>Bernards</surname><given-names>R</given-names></name><name><surname>Friend</surname><given-names>SH</given-names></name></person-group><article-title>Gene expression profiling predicts clinical outcome of breast cancer</article-title><source>Nature</source><year>2002</year><volume>415</volume><fpage>530</fpage><lpage>536</lpage><pub-id pub-id-type="pmid">11823860</pub-id><pub-id pub-id-type="doi">10.1038/415530a</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Eeckhoute</surname><given-names>J</given-names></name><name><surname>Keeton</surname><given-names>EK</given-names></name><name><surname>Lupien</surname><given-names>M</given-names></name><name><surname>Krum</surname><given-names>SA</given-names></name><name><surname>Carroll</surname><given-names>JS</given-names></name><name><surname>Brown</surname><given-names>M</given-names></name></person-group><article-title>Positive cross-regulatory loop ties GATA-3 to estrogen receptor alpha expression in breast cancer</article-title><source>Cancer Res</source><year>2007</year><volume>67</volume><fpage>6477</fpage><lpage>6483</lpage><pub-id pub-id-type="pmid">17616709</pub-id><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-07-0746</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>J</given-names></name><name><surname>Ruschhaupt</surname><given-names>M</given-names></name><name><surname>Buness</surname><given-names>A</given-names></name><name><surname>Asslaber</surname><given-names>M</given-names></name><name><surname>Regitnig</surname><given-names>P</given-names></name><name><surname>Zatloukal</surname><given-names>K</given-names></name><name><surname>Schippinger</surname><given-names>W</given-names></name><name><surname>Ploner</surname><given-names>F</given-names></name><name><surname>Poustka</surname><given-names>A</given-names></name><name><surname>Sultmann</surname><given-names>H</given-names></name></person-group><article-title>Identification and meta-analysis of a small gene expression signature for the diagnosis of estrogen receptor status in invasive ductal breast cancer</article-title><source>Int J Cancer</source><year>2006</year><volume>119</volume><fpage>2974</fpage><lpage>2979</lpage><pub-id pub-id-type="pmid">17019712</pub-id><pub-id pub-id-type="doi">10.1002/ijc.22234</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Oh</surname><given-names>DS</given-names></name><name><surname>Troester</surname><given-names>MA</given-names></name><name><surname>Usary</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>Z</given-names></name><name><surname>He</surname><given-names>X</given-names></name><name><surname>Fan</surname><given-names>C</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Carey</surname><given-names>LA</given-names></name><name><surname>Perou</surname><given-names>CM</given-names></name></person-group><article-title>Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers</article-title><source>J Clin Oncol</source><year>2006</year><volume>24</volume><fpage>1656</fpage><lpage>1664</lpage><pub-id pub-id-type="pmid">16505416</pub-id><pub-id pub-id-type="doi">10.1200/JCO.2005.03.2755</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kouros-Mehr</surname><given-names>H</given-names></name><name><surname>Bechis</surname><given-names>SK</given-names></name><name><surname>Slorach</surname><given-names>EM</given-names></name><name><surname>Littlepage</surname><given-names>LE</given-names></name><name><surname>Egeblad</surname><given-names>M</given-names></name><name><surname>Ewald</surname><given-names>AJ</given-names></name><name><surname>Pai</surname><given-names>SY</given-names></name><name><surname>Ho</surname><given-names>IC</given-names></name><name><surname>Werb</surname><given-names>Z</given-names></name></person-group><article-title>GATA-3 links tumor differentiation and dissemination in a luminal breast cancer model</article-title><source>Cancer Cell</source><year>2008</year><volume>13</volume><fpage>141</fpage><lpage>152</lpage><pub-id pub-id-type="pmid">18242514</pub-id><pub-id pub-id-type="doi">10.1016/j.ccr.2008.01.011</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>BJ</given-names></name><name><surname>Giguere</surname><given-names>V</given-names></name></person-group><article-title>Identification of novel pathway partners of p68 and p72 RNA helicases through Oncomine meta-analysis</article-title><source>BMC Genomics</source><year>2007</year><volume>8</volume><fpage>419</fpage><pub-id pub-id-type="pmid">18005418</pub-id><pub-id pub-id-type="doi">10.1186/1471-2164-8-419</pub-id></citation></ref><ref id="B13"><citation citation-type="other"><article-title>Oncomine</article-title><ext-link ext-link-type="uri" xlink:href="http://www.oncomine.org"/></citation></ref><ref id="B14"><citation citation-type="other"><article-title>Genecards</article-title><ext-link ext-link-type="uri" xlink:href="http://www.genecards.org"/></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barry</surname><given-names>JB</given-names></name><name><surname>Laganiere</surname><given-names>J</given-names></name><name><surname>Giguere</surname><given-names>V</given-names></name></person-group><article-title>A single nucleotide in an estrogen-related receptor alpha site can dictate mode of binding and peroxisome proliferator-activated receptor gamma coactivator 1alpha activation of target promoters</article-title><source>Mol Endocrinol</source><year>2006</year><volume>20</volume><fpage>302</fpage><lpage>310</lpage><pub-id pub-id-type="pmid">16150865</pub-id><pub-id pub-id-type="doi">10.1210/me.2005-0313</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tozlu</surname><given-names>S</given-names></name><name><surname>Girault</surname><given-names>I</given-names></name><name><surname>Vacher</surname><given-names>S</given-names></name><name><surname>Vendrell</surname><given-names>J</given-names></name><name><surname>Andrieu</surname><given-names>C</given-names></name><name><surname>Spyratos</surname><given-names>F</given-names></name><name><surname>Cohen</surname><given-names>P</given-names></name><name><surname>Lidereau</surname><given-names>R</given-names></name><name><surname>Bieche</surname><given-names>I</given-names></name></person-group><article-title>Identification of novel genes that co-cluster with estrogen receptor alpha in breast tumor biopsy specimens, using a large-scale real-time reverse transcription-PCR approach</article-title><source>Endocr Relat Cancer</source><year>2006</year><volume>13</volume><fpage>1109</fpage><lpage>1120</lpage><pub-id pub-id-type="pmid">17158757</pub-id><pub-id pub-id-type="doi">10.1677/erc.1.01120</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Abba</surname><given-names>MC</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>H</given-names></name><name><surname>Drake</surname><given-names>JA</given-names></name><name><surname>Gaddis</surname><given-names>S</given-names></name><name><surname>Baggerly</surname><given-names>K</given-names></name><name><surname>Sahin</surname><given-names>A</given-names></name><name><surname>Aldaz</surname><given-names>CM</given-names></name></person-group><article-title>Gene expression signature of estrogen receptor alpha status in breast cancer</article-title><source>BMC Genomics</source><year>2005</year><volume>6</volume><fpage>37</fpage><pub-id pub-id-type="pmid">15762987</pub-id><pub-id pub-id-type="doi">10.1186/1471-2164-6-37</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Laganiere</surname><given-names>J</given-names></name><name><surname>Deblois</surname><given-names>G</given-names></name><name><surname>Lefebvre</surname><given-names>C</given-names></name><name><surname>Bataille</surname><given-names>AR</given-names></name><name><surname>Robert</surname><given-names>F</given-names></name><name><surname>Giguere</surname><given-names>V</given-names></name></person-group><article-title>From the Cover: Location analysis of estrogen receptor alpha target promoters reveals that FOXA1 defines a domain of the estrogen response</article-title><source>Proc Natl Acad Sci USA</source><year>2005</year><volume>102</volume><fpage>11651</fpage><lpage>11656</lpage><pub-id pub-id-type="pmid">16087863</pub-id><pub-id pub-id-type="doi">10.1073/pnas.0505575102</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Carroll</surname><given-names>JS</given-names></name><name><surname>Liu</surname><given-names>XS</given-names></name><name><surname>Brodsky</surname><given-names>AS</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Meyer</surname><given-names>CA</given-names></name><name><surname>Szary</surname><given-names>AJ</given-names></name><name><surname>Eeckhoute</surname><given-names>J</given-names></name><name><surname>Shao</surname><given-names>W</given-names></name><name><surname>Hestermann</surname><given-names>EV</given-names></name><name><surname>Geistlinger</surname><given-names>TR</given-names></name><name><surname>Fox</surname><given-names>EA</given-names></name><name><surname>Silver</surname><given-names>PA</given-names></name><name><surname>Brown</surname><given-names>M</given-names></name></person-group><article-title>Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1</article-title><source>Cell</source><year>2005</year><volume>122</volume><fpage>33</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">16009131</pub-id><pub-id pub-id-type="doi">10.1016/j.cell.2005.05.008</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Usary</surname><given-names>J</given-names></name><name><surname>Llaca</surname><given-names>V</given-names></name><name><surname>Karaca</surname><given-names>G</given-names></name><name><surname>Presswala</surname><given-names>S</given-names></name><name><surname>Karaca</surname><given-names>M</given-names></name><name><surname>He</surname><given-names>X</given-names></name><name><surname>Langerod</surname><given-names>A</given-names></name><name><surname>Karesen</surname><given-names>R</given-names></name><name><surname>Oh</surname><given-names>DS</given-names></name><name><surname>Dressler</surname><given-names>LG</given-names></name><name><surname>Lonning</surname><given-names>PE</given-names></name><name><surname>Strausberg</surname><given-names>RL</given-names></name><name><surname>Chanock</surname><given-names>S</given-names></name><name><surname>Borresen-Dale</surname><given-names>AL</given-names></name><name><surname>Perou</surname><given-names>CM</given-names></name></person-group><article-title>Mutation of GATA3 in human breast tumors</article-title><source>Oncogene</source><year>2004</year><volume>23</volume><fpage>7669</fpage><lpage>7678</lpage><pub-id pub-id-type="pmid">15361840</pub-id><pub-id pub-id-type="doi">10.1038/sj.onc.1207966</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Dai</surname><given-names>JL</given-names></name></person-group><article-title>Suppression of breast cancer cell growth by Na+/H+ exchanger regulatory factor 1 (NHERF1)</article-title><source>Breast Cancer Res</source><year>2006</year><volume>8</volume><fpage>R63</fpage><pub-id pub-id-type="pmid">17078868</pub-id><pub-id pub-id-type="doi">10.1186/bcr1616</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Collins</surname><given-names>C</given-names></name><name><surname>Rommens</surname><given-names>JM</given-names></name><name><surname>Kowbel</surname><given-names>D</given-names></name><name><surname>Godfrey</surname><given-names>T</given-names></name><name><surname>Tanner</surname><given-names>M</given-names></name><name><surname>Hwang</surname><given-names>SI</given-names></name><name><surname>Polikoff</surname><given-names>D</given-names></name><name><surname>Nonet</surname><given-names>G</given-names></name><name><surname>Cochran</surname><given-names>J</given-names></name><name><surname>Myambo</surname><given-names>K</given-names></name><name><surname>Jay</surname><given-names>KE</given-names></name><name><surname>Froula</surname><given-names>J</given-names></name><name><surname>Cloutier</surname><given-names>T</given-names></name><name><surname>Kuo</surname><given-names>WL</given-names></name><name><surname>Yaswen</surname><given-names>P</given-names></name><name><surname>Dairkee</surname><given-names>S</given-names></name><name><surname>Giovanola</surname><given-names>J</given-names></name><name><surname>Hutchinson</surname><given-names>GB</given-names></name><name><surname>Isola</surname><given-names>J</given-names></name><name><surname>Kallioniemi</surname><given-names>OP</given-names></name><name><surname>Palazzolo</surname><given-names>M</given-names></name><name><surname>Martin</surname><given-names>C</given-names></name><name><surname>Ericsson</surname><given-names>C</given-names></name><name><surname>Pinkel</surname><given-names>D</given-names></name><name><surname>Albertson</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>WB</given-names></name><name><surname>Gray</surname><given-names>JW</given-names></name></person-group><article-title>Positional cloning of ZNF217 and NABC1: genes amplified at 20q13.2 and overexpressed in breast carcinoma</article-title><source>Proc Natl Acad Sci USA</source><year>1998</year><volume>95</volume><fpage>8703</fpage><lpage>8708</lpage><pub-id pub-id-type="pmid">9671742</pub-id><pub-id pub-id-type="doi">10.1073/pnas.95.15.8703</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Correa</surname><given-names>RG</given-names></name><name><surname>de Carvalho</surname><given-names>AF</given-names></name><name><surname>Pinheiro</surname><given-names>NA</given-names></name><name><surname>Simpson</surname><given-names>AJ</given-names></name><name><surname>de Souza</surname><given-names>SJ</given-names></name></person-group><article-title>NABC1 (BCAS1): alternative splicing and downregulation in colorectal tumors</article-title><source>Genomics</source><year>2000</year><volume>65</volume><fpage>299</fpage><lpage>302</lpage><pub-id pub-id-type="pmid">10857754</pub-id><pub-id pub-id-type="doi">10.1006/geno.2000.6172</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Beardsley</surname><given-names>DI</given-names></name><name><surname>Kowbel</surname><given-names>D</given-names></name><name><surname>Lataxes</surname><given-names>TA</given-names></name><name><surname>Mannino</surname><given-names>JM</given-names></name><name><surname>Xin</surname><given-names>H</given-names></name><name><surname>Kim</surname><given-names>WJ</given-names></name><name><surname>Collins</surname><given-names>C</given-names></name><name><surname>Brown</surname><given-names>KD</given-names></name></person-group><article-title>Characterization of the novel amplified in breast cancer-1 (NABC1) gene product</article-title><source>Exp Cell Res</source><year>2003</year><volume>290</volume><fpage>402</fpage><lpage>413</lpage><pub-id pub-id-type="pmid">14567997</pub-id><pub-id pub-id-type="doi">10.1016/S0014-4827(03)00353-7</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Abba</surname><given-names>MC</given-names></name><name><surname>Nunez</surname><given-names>MI</given-names></name><name><surname>Colussi</surname><given-names>AG</given-names></name><name><surname>Croce</surname><given-names>MV</given-names></name><name><surname>Segal-Eiras</surname><given-names>A</given-names></name><name><surname>Aldaz</surname><given-names>CM</given-names></name></person-group><article-title>GATA3 protein as a MUC1 transcriptional regulator in breast cancer cells</article-title><source>Breast Cancer Res</source><year>2006</year><volume>8</volume><fpage>R64</fpage><pub-id pub-id-type="pmid">17078870</pub-id><pub-id pub-id-type="doi">10.1186/bcr1617</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zaretsky</surname><given-names>JZ</given-names></name><name><surname>Barnea</surname><given-names>I</given-names></name><name><surname>Aylon</surname><given-names>Y</given-names></name><name><surname>Gorivodsky</surname><given-names>M</given-names></name><name><surname>Wreschner</surname><given-names>DH</given-names></name><name><surname>Keydar</surname><given-names>I</given-names></name></person-group><article-title>MUC1 gene overexpressed in breast cancer: structure and transcriptional activity of the MUC1 promoter and role of estrogen receptor alpha (ERalpha) in regulation of the MUC1 gene expression</article-title><source>Mol Cancer</source><year>2006</year><volume>5</volume><fpage>57</fpage><pub-id pub-id-type="pmid">17083744</pub-id><pub-id pub-id-type="doi">10.1186/1476-4598-5-57</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Naylor</surname><given-names>MJ</given-names></name><name><surname>Ormandy</surname><given-names>CJ</given-names></name></person-group><article-title>Gata-3 and mammary cell fate</article-title><source>Breast Cancer Res</source><year>2007</year><volume>9</volume><fpage>302</fpage><pub-id pub-id-type="pmid">17381824</pub-id><pub-id pub-id-type="doi">10.1186/bcr1661</pub-id></citation></ref></ref-list></back></article> 